Syngene International Ltd Falls to 52-Week Low of Rs 429

Stock Price Movement and Market Context

On 13 Feb 2026, Syngene International Ltd’s share price touched an intraday low of Rs.429, representing a 3.74% drop on the day and a 3.09% decline in the closing price. This marks the lowest level the stock has traded at in the past year, down sharply from its 52-week high of Rs.760.95. The stock has been on a losing streak for two consecutive days, cumulatively falling by 5.4% during this period.

The stock’s performance today notably underperformed its sector by 2.29%, reflecting broader pressures within the Healthcare Services industry. Syngene’s share price is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum.

Meanwhile, the broader market context shows the Sensex opened lower at 82,902.73, down 772.19 points or 0.92%, and was trading at 82,917.45 (-0.91%) during the same session. Despite this, the Sensex remains relatively close to its 52-week high of 86,159.02, just 3.91% away, and is positioned above its 200-day moving average, indicating a more resilient market backdrop compared to Syngene’s stock.

Long-Term and Recent Performance Metrics

Over the past year, Syngene International Ltd has delivered a total return of -38.30%, significantly underperforming the Sensex, which posted an 8.90% gain over the same period. This underperformance extends beyond the last year, with the stock lagging the BSE500 index across one-year, three-year, and three-month timeframes.

Financially, the company’s growth trajectory has been modest at best. Net sales have increased at an annualised rate of 11.77% over the last five years, while operating profit growth has been more subdued at 5.36% annually. These figures suggest a relatively slow expansion in core business operations compared to sector peers.

Recent Quarterly Results and Profitability Concerns

The company’s latest quarterly results for December 2025 reveal a notable decline in profitability. Profit Before Tax (PBT) excluding other income stood at Rs.83.60 crores, down 37.8% compared to the average of the previous four quarters. Net Profit After Tax (PAT) for the quarter was Rs.52.29 crores, a steep fall of 55.3% relative to the prior four-quarter average. Earnings Per Share (EPS) also hit a low of Rs.0.37, reflecting the subdued earnings environment.

Return on Equity (ROE) remains modest at 9.9%, while the stock’s valuation metrics indicate a premium positioning with a Price to Book Value ratio of 3.8. This valuation is considered expensive relative to the company’s historical averages and peer group, especially in light of the declining profit trends.

Over the last year, profits have contracted by 18.5%, further underscoring the challenges faced by the company in maintaining earnings growth.

Credit Profile and Institutional Ownership

On a positive note, Syngene International Ltd maintains a conservative capital structure with an average Debt to Equity ratio of zero, indicating no reliance on debt financing. This low leverage reduces financial risk and interest burden, which could be a stabilising factor amid earnings pressure.

Institutional investors hold a significant stake in the company, accounting for 40.8% of share ownership. This level of institutional participation suggests that well-resourced investors continue to monitor the company’s fundamentals closely.

Summary of Key Metrics and Market Position

Syngene International Ltd currently holds a Mojo Score of 28.0 and has been assigned a Mojo Grade of Strong Sell as of 19 Jan 2026, an upgrade from the previous Sell rating. The company’s Market Cap Grade stands at 3, reflecting its mid-tier market capitalisation within the Healthcare Services sector.

The stock’s recent price action and financial results highlight a period of subdued growth and profitability pressures, with valuation levels that remain elevated relative to earnings performance. The stock’s underperformance relative to the Sensex and sector peers over multiple time horizons further illustrates the challenges faced by the company in delivering shareholder returns.

Despite the broader market’s relative strength, Syngene’s share price continues to trend lower, reflecting investor caution amid the company’s financial metrics and valuation concerns.

Conclusion

Syngene International Ltd’s fall to a 52-week low of Rs.429 marks a significant milestone in its recent share price trajectory. The stock’s decline is underpinned by a combination of weak quarterly earnings, modest long-term growth rates, and a valuation premium that contrasts with its financial performance. While the company benefits from a strong institutional investor base and a debt-free balance sheet, these factors have not yet translated into positive momentum in the stock price. The current market environment and company fundamentals suggest a cautious outlook for the stock’s near-term performance.

Unlock special upgrade rates for a limited period. Start Saving Now →